Home
Company Profile
Our Products
Contact Us
Select Language 
English
Spanish
French
German
Italian
Chinese (Simplified)
Japanese
Korean
Arabic
Portuguese
0.5mg Neostigmine Methylsulphate Injection IP
0.5mg Neostigmine Methylsulphate Injection IP
Price And Quantity
- Box/Boxes
- 1-50
- Box/Boxes
- 30 INR
Product Specifications
- Injection
- Liquid
- 0.5 mg
- As Suggested
- cold & dry place
Product Description
0.5mg Neostigmine Methylsulphate Injection IP is a medication used to treat myasthenia gravis, a neuromuscular disorder. It is an injectable form of neostigmine, a cholinesterase inhibitor, which helps to increase the transmission of nerve impulses to muscles. This medication is available in a liquid form for injection and is to be administered by a medical professional. It is supplied in a 0.5 mg dosage and should be stored in a cool and dry place. This medication is manufactured by a reliable supplier and is exported, supplied, and traded in the market. It is prescribed by a doctor and is used to treat myasthenia gravis, a neuromuscular disorder that affects the transmission of nerve impulses to muscles. It is available in an injectable form and should be administered by a qualified medical professional.
FAQ :
Q: What is 0.5mg Neostigmine Methylsulphate Injection IP?
A: 0.5mg Neostigmine Methylsulphate Injection IP is a medication used to treat myasthenia gravis, a neuromuscular disorder. It is an injectable form of neostigmine, a cholinesterase inhibitor, which helps to increase the transmission of nerve impulses to muscles.
Q: What is the dosage of 0.5mg Neostigmine Methylsulphate Injection IP?
A: 0.5mg Neostigmine Methylsulphate Injection IP is supplied in a 0.5 mg dosage and should be administered by a medical professional.
Q: How should 0.5mg Neostigmine Methylsulphate Injection IP be stored?
A: 0.5mg Neostigmine Methylsulphate Injection IP should be stored in a cool and dry place.
Q: Who manufactures 0.5mg Neostigmine Methylsulphate Injection IP?
A: 0.5mg Neostigmine Methylsulphate Injection IP is manufactured by a reliable supplier and is exported, supplied, and traded in the market.
Q: What is the drug type of 0.5mg Neostigmine Methylsulphate Injection IP?
A: 0.5mg Neostigmine Methylsulphate Injection IP is an injectable form of medication.
Q: What is the physical form of 0.5mg Neostigmine Methylsulphate Injection IP?
A: 0.5mg Neostigmine Methylsulphate Injection IP is available in a liquid form for injection.
Q: What is the dosage guidelines of 0.5mg Neostigmine Methylsulphate Injection IP?
A: The dosage guidelines of 0.5mg Neostigmine Methylsulphate Injection IP should be as suggested by the doctor.
A: 0.5mg Neostigmine Methylsulphate Injection IP is a medication used to treat myasthenia gravis, a neuromuscular disorder. It is an injectable form of neostigmine, a cholinesterase inhibitor, which helps to increase the transmission of nerve impulses to muscles.
Q: What is the dosage of 0.5mg Neostigmine Methylsulphate Injection IP?
A: 0.5mg Neostigmine Methylsulphate Injection IP is supplied in a 0.5 mg dosage and should be administered by a medical professional.
Q: How should 0.5mg Neostigmine Methylsulphate Injection IP be stored?
A: 0.5mg Neostigmine Methylsulphate Injection IP should be stored in a cool and dry place.
Q: Who manufactures 0.5mg Neostigmine Methylsulphate Injection IP?
A: 0.5mg Neostigmine Methylsulphate Injection IP is manufactured by a reliable supplier and is exported, supplied, and traded in the market.
Q: What is the drug type of 0.5mg Neostigmine Methylsulphate Injection IP?
A: 0.5mg Neostigmine Methylsulphate Injection IP is an injectable form of medication.
Q: What is the physical form of 0.5mg Neostigmine Methylsulphate Injection IP?
A: 0.5mg Neostigmine Methylsulphate Injection IP is available in a liquid form for injection.
Q: What is the dosage guidelines of 0.5mg Neostigmine Methylsulphate Injection IP?
A: The dosage guidelines of 0.5mg Neostigmine Methylsulphate Injection IP should be as suggested by the doctor.
Trade Information
- Cash Advance (CA)
- 50000 Per Month
- 8-10 Days
- Western Europe Asia Australia Eastern Europe Middle East Central America South America North America Africa
Contact Us